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Synopsis 
Insulin stimulates endothelial nitric oxide synthesis via protein kinase B/Akt-mediated phosphorylation 
and activation of endothelial nitric oxide synthase at Ser1177. In previous studies, we have demonstrated 
that stimulation of endothelial nitric oxide  synthase phosphorylation at Ser1177 may be required, yet is 
not sufficient for insulin-stimulated nitric oxide synthesis.  We therefore investigated the role of 
phosphorylation of endothelial nitric oxide synthase at alternative sites to Ser1177 as candidate parallel 
mechanisms contributing to insulin-stimulated nitric oxide synthesis. Stimulation of human aortic 
endothelial cells with insulin rapidly stimulated phosphorylation of both Ser615 and Ser1177 on 
endothelial NO synthase , whereas phosphorylation of Ser114, Thr495 and Ser633 was unaffected.  
Insulin-stimulated Ser615 phosphorylation was abrogated by incubation with the phosphatidylinositol-3’-
kinase inhibitor, wortmannin, infection with adenoviruses expressing a dominant negative mutant protein 
kinase B/Akt or preincubation with tumour  necrosis factor-alpha but was unaffected by high culture 
glucose concentrations. Mutation of Ser615 to Ala615 reduced insulin-stimulated nitric oxide synthesis , 
whereas mutation of Ser615 to Asp615 increased nitric oxide production by nitric oxide synthase in 
which Ser1177 had been mutated to an Asp1177.  We propose that the rapid, protein kinase B-mediated 
stimulation of phosphorylation of Ser615 contributes to insulin-stimulated nitric oxide synthesis.  
 
KEYWORDS: eNOS, signalling, endothelium 
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INTRODUCTION 
Type 2 diabetes is associated with a greatly increased risk of atherosclerosis, yet the molecular 
mechanisms that underlie this association remain poorly characterised.  Endothelial dysfunction, 
characterised by reduced nitric oxide (NO) bioavailability, is a key early event in the development of 
atherosclerosis [reviewed in 1].  NO is a key regulator of vascular homeostasis, synthesised by endothelial 
NO synthase (eNOS). Insulin is a direct-acting vasodilator in intact vessels  that has been proposed to 
contribute to the maintenance of vascular health [2-4], and we and others have demonstrated that insulin  
stimulates NO synthesis in cultured human endothelial cells  [5-6].  Insulin-stimulated NO synthesis is, at 
least in part, the result of phosphatidylinositol-3’-kinase (PI3K) activation and the subsequent stimulation 
of protein kinase B (PKB/Akt), with resultant phosphorylation and activation of endothelial NO synthase 
(eNOS) at Ser1177 [6-7].  Furthermore, we have previously demonstrated that culture of human aortic 
endothelial cells (HAECs) in high glucose abrogated insulin-stimulated NO synthesis, without altering 
insulin-stimulated phosphorylation of eNOS at Ser1177 or Ca2+-stimulated NO synthesis [6].  These data 
indicate that stimulation of PKB and subsequent phosphorylation of eNOS Ser1177 may be required, yet 
not sufficient, for insulin-stimulated NO synthesis under certain conditions. This, in turn, suggests that 
insulin-stimulated NO synthesis is mediated by more than one signalling mechanism.  One candidate 
mechanism that might underlie insulin-stimulated NO synthesis independent of Ser1177 phosphorylation 
is the regulation of eNOS by phosphorylation at sites other than Ser1177. We have previously 
demonstrated that phosphorylation of eNOS at Thr495 is unaffected by insulin [6]. Phosphorylation of 
eNOS at Ser114, Ser615 and Ser633 have been reported to regulate eNOS activity in response to various 
stimuli [8-11], yet the effect of acute insulin stimulation on eNOS phosphorylaton at these alternative 
sites has yet to be determined.   In the current study we investigated the role of phosphorylation of eNOS 
at alternative sites to Ser1177 as potential mechanisms contributing to insulin-stimulated NO synthesis. 
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EXPERIMENTAL 
Materials - 
Cryopreserved HAECs were purchased from Promocell and large vessel endothelial cell media 
obtained from TCS Cellworks. Human eNOS cDNA cloned into pcDNA3.1 was a kind gift from Prof. 
Keith Channon (University of Oxford, Oxford, UK).  NADPH, phenformin and tetrahydrobiopterin (BH4) 
were obtained from Sigma.  Calmodulin (CaM) was obtained from Merck.  Rabbit anti-phospho-eNOS 
Ser116 (07-357), anti-phospho-eNOS Ser617 (07-561) and anti-phospho-eNOS Ser635 (07-562) 
(corresponding to Ser114, Ser615 and Ser633 in human eNOS) antibodies were obtained from Upstate 
Biotech. All other reagents were from sources described previously [6,12-13]. 
 
Cell Culture –  
 HAECs were grown in large vessel endothelial cell medium and passaged when at 80% 
confluence as described previously [6,12-13]. Cells were used for experiments between passages 3 and 6.  
HeLa cells were maintained in DMEM supplemented with 10% (v/v) foetal calf serum, 100 U/ml 
penicillin, 100 mg/l streptomycin, in a humidified atmosphere of 95% (v/v) air: 5% (v/v) CO2 at 37oC.   
 
Preparation of adenoviruses and infection of HAECs –  
Adenoviruses expressing dominant negative PKB (Ad.PKB-DN), constitutively active PKB 
(Ad.PKB-CA) or control adenoviruses (Ad.control) were propagated and purified as described previously 
[14].  HAECs w ere infected with 5 pfu/cell adenovirus in complete medium and the cells cultured for  48 h 
prior to experimentation, with the final 24 h in serum-free medium. Under these conditions after infection 
with a green fluorescent protein (GFP)-expressing virus, the majority (>95%) of HAECs expressed GFP.  
 
Site-directed mutagenesis of eNOS – 
Ser615Asp, Ser615Ala, Ser1177Asp and Ser1177Ala mutations were introduced into human 
eNOS using a QuikChange site-directed mutagenesis kit (Stratagene) using the following primers: 
Ser615Ala forward 5’ -ATAAGATCCGCTTCAACGCCATCTCCTGCTCAGACCC-3’; Ser615Ala 
reverse 5’-GGGTCTGAGCAGGAGATGGCGTTGAAGCGGATCTTAT-3’; Ser615Asp forward 5’ -
ATAAGATCCGCTTCAACGACATCTCCTGCTCAGACCC-3’; Ser615Asp reverse 5’ -
GGGTCTGAGCAGGAGATGTCGTTGAAGCGGATCTTAT-3’; Ser1177Ala forward 5’ -
GCCGCATACGCACCCAGGCCTTTTCCTTGCAGGAGCG-3’; Ser1177Ala reverse 5’ -
CGCTCCTGCAAGGAAAAGGCCTGGGTGCGTATGCGGC -3’; Ser1177Asp forward 5’ -
GCCGCATACGCACCCAGGACTTTTCCTTGCAGGAGCG-3’; Ser1177Asp reverse 5’ -
CGCTCCTGCAAGGAAAAGTCCTGGGTGCGTATGCGGC-3’. Mutant generation was confirmed by 
sequencing analysis (University of Dundee Sequencing Service, Dundee, UK). 
 
Transfection of HeLa cells - 
Mutant DNA (2 µg/well) was mixed with Lipofectamine 2000 (Invitrogen, 4 ml/well) in Opti-
MEM reduced serum medium (Invitrogen, 200 ml) and added to HeLa cells plated on 12-well plates in 
serum-free culture medium without antibiotics.  Cells were incubated for 24 h in the presence or absence 
of insulin for the final 5 min, washed with ice-cold PBS and ice-cold lysis buffer (50 mM Tris-HCl pH7.4 
at 4°C, 50 mM NaF, 1% (v/v) Triton X-100, 250 mM mannitol, 5 mM Na4P 2O7, 1 mM Na3VO4, 1 mM 
EDTA, 1 mM EGTA, 1 mM dithiothreitol, 1 mM benzamidine, 0.1 mM phenylmethylsulphonyl fluoride, 
5 mg/l soybean trypsin inhibitor, 80 m l) was added to each well. Cells were scraped into a fresh 
microcentrifuge tube and centrifuged (11,000 x g, 3 min, 4ºC). The supernatant was then collected and 
stored at -20ºC prior to analysis. 
 
Preparation of cell lysates, SDS PAGE and Western Blotting  –  
Cell lysates were prepared, proteins resolved by SDS-PAGE and subjected to western blotting 
with the antibodies indicated as described previously [6,12-13].   
 
Evaluation of NO synthesis in cell lysates - 
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Cell lysates (100 mg) were added to 100 ml 25% (v/v) 2’-5’-ADP Sepharose in Hepes-buffered 
saline (HBS) (135 mM NaCl, 5.9 mM KCl, 1.2 mM MgCl2, 11.6 mM Hepes-NaOH pH7.3) and the 
volume made up to 300 m l with HBS.  After incubation at 4oC for 3 h on a rotating mixer, beads were 
washed twice with 1 ml HBS, twice with 1 ml HBS containing 2 mM EGTA and twice with 1 ml HBS.  
Pellets were resuspended in 250 ml assay buffer (HBS containing 30 mM BH4, 100 mM L-arginine, 1 mM 
CaCl2, 3 mM NADPH) and divided into 50 m l aliquots. To each aliquot CaM was added to a final 
concentration of 0, 10, 20, 100 or 200 nM.  Reactions were incubated at 37oC for 30 min and 100 ml of 
ice-cold ethanol added prior to centrifugation (11,000 x g, 3 min, 4oC). Supernatants were assayed for 
NO2- content using a Sievers 280A NO analyser as described previously [6,12-13]. 
 
Evaluation of NO synthesis in cells - 
HeLa cells cultured in 12-well plates were incubated in serum-free medium overnight.  Cells were 
preincubated for 1 h at 37°C in 0.5 ml/well Krebs Ringer Hepes (KRH) buffer (119 mM NaCl, 4.75 mM 
KCl, 1.2 mM MgSO4, 5 mM NaHCO3, 1.3 mM CaCl2, 20 mM Hepes-NaOH pH7.4, 1.3 mM KH2PO4, 5 
mM glucose).  The medium was removed and replaced with fresh KRH buffer (0.5 ml/well) in the 
presence of various concentrations of test substances.  After incubation for various durations, aliquots of 
media were removed and analyzed using a Sievers 280A NO analyzer as described previously  [6,12-13]. 
The appropriate control experiments were performed in the presence of the eNOS inhibitor, L-NG-
monomethyl arginine (L-NMMA, 0.1 mM). Data is presented as L -NMMA-sensitive NO synthesis.  
 
Statistics - 
Unless stated otherwise, results are expressed as the mean ± SEM. Statistically significant 
differences were determined using a two-tailed Student’s t test, with p<0. 05 deemed significant. 
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RESULTS  
Insulin stimulated a significant increase in eNOS phosphorylation at Ser1177 and Ser615 in 
HAECs (approximately 1.7-fold), yet had no effect on eNOS phosphorylation at Ser114, Thr495 or 
Ser633 (Figure 1).  High (25 mM) culture glucose had no effect on basal or insulin-stimulated 
phosphorylation of eNOS at any site examined, with the exception of Ser114, which demonstrated 
reduced phosphorylation (approximately 30% ) in the presence of insulin (Figure 1). Insulin-stimulated 
eNOS Ser615 phosphorylation was inhibited by preincubation with wortmannin or infection of HAECs 
with Ad.PKB-DN (Figure 2).  Infection of HAECs with Ad.PKB-CA caused a significant increase in 
basal eNOS Ser615 phosphorylation (Figure 2).  Vascular endothelial growth factor (VEGF), which also 
stimulates PKB, stimulated eNOS Ser615 phosphorylation and insulin-stimulated Ser615 phosphorylation 
was concomitant with Ser1177 phosphorylation (data not shown).    
AMP-activated protein kinase (AMPK) has also been demonstrated to phosphorylate and activate 
eNOS at Ser1177 [12-13,15]. Incubation of HAECs with the AMPK activator phenformin stimulated 
phosphorylation of the AMPK substrate acetyl CoA carboxylase and phosphorylation of eNOS at 
Ser1177, without altering phosphorylation of  eNOS at Ser615 or PKB at Ser473 (Figure 3).   TNFa has 
previously been reported to inhibit insulin-stimulated NO synthesis and eNOS Ser1179 (Bovine 
equivalent to Ser1177) phosphorylation in bovine aortic endothelial cells (BAECs) and reduce insulin 
receptor phosphorylation in HAECs [9,16].  TNFa significantly attenuated insulin-stimulated eNOS 
Ser615 phosphorylation and PKB Ser473 phosphorylation in HAECs (Figure 3).  
As these data indicate that insulin-stimulated phosphorylation of eNOS at both Ser1177 and 
Ser615 are mediated by PI3K/PKB, we reasoned that concurrent phosphorylation at both sites would 
influence eNOS activity.  HeLa cells (with low endogenous expression of eNOS) were transfected with 
eNOS mutants in which Ser615 and/or Ser1177 had been mutated to Ala (phospho-null) or Asp (phospho-
mimetic).  Transfection efficiency was approximately equal in each case and mutation of Ser615 had no 
effect on insulin-stimulated Ser1177 phosphorylation. Similarly, mutation of Ser1177 had no effect on 
insulin-stimulated Ser615 phosphorylation (Figure 4A). In unstimulated HeLa cells, Ser615 and Ser1177 
phosphorylation was barely detectable (data not shown).  ADP Sepharose-purified extracts from 
untransfected HeLa cells exhibited low levels of NO synthesis that were not sensitive to CaM addition, 
whereas cells transfected with wild type human eNOS exhibited Ca2+-sensitive NO synthesis (Table 1).  
Ca2+-sensitive NO synthesis was not significantly different in Ala615 or Asp615 mutants (Table 1). In 
contrast, eNOS activity was significantly reduced at 200 nM CaM in the Ala1177 mutant and 
significantly increased at 10-200 nM CaM in the Asp1177 mutant (Table 1).  Mutation of Ser615 to Ala 
or Asp had no significant effect on eNOS activity or Ca2+ sensitivity in the Ala1177 mutant, yet mutation 
of Ser615 to Ala significantly reduced Asp1177 mutant eNOS activity at 20-100 nM CaM and eNOS 
activity was significantly increased at 100-200 nM CaM in the double Asp615-Asp1177 mutant 
compared to the Asp1177 single mutant (Table 1).   
Intact HeLa cells transfected with wild type, Ala615 or Asp615 mutant eNOS exhibited insulin-
stimulated NO synthesis, whereas NO synthesis was barely detectable  in untransfected cells.  Basal NO 
synthesis was significantly increased compared to wild type in cells transfected with Asp1177, Ala615-
Asp1177 and Asp615-Asp1177 mutant eNOS (Figure 4B).  In addition, insulin-stimulated NO synthesis 
was significantly reduced in cells transfected with the Ala615 mutant compared to wild type (Figure 4B).  
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DISCUSSION 
 The principal finding of this study was that insulin rapidly stimulates phosphorylation of eNOS at 
Ser615.  Phosphorylation at Ser615 was concomitant with insulin -stimulated phosphorylation of eNOS at 
Ser1177 and attenuated by the PI3K inhibitor, wortmannin, or infection with adenoviruses expressing 
dominant-negative mutant PKB. Furthermore, downregulation of Ser615 phosphorylation attenuates 
insulin-stimulated NO synthesis.   
 Phosphorylation of eNOS at Ser617 (bovine sequence) has previously been demonstrated in 
response to bradykinin, VEGF, ATP , endostatin and statins in BAECs [9-11,17]. The current study 
represents the first evidence of Ser615 phosphorylation in human endothelial cells and identifies insulin 
as a novel stimulus for Ser615 phosphorylation.  Inhibition of PI3K has previously been reported to 
attenuate bradykinin - and lovastatin -stimulated Ser617 phosphorylation  [10-11].  Furthermore, the 
sequence surrounding Ser615 forms a consensus PKB phosphorylation site and recombinant PKB isolated 
from wortmannin-treated cells has a  reduced capacity to phosphorylate eNOS Ser617 in vitro  [10].  In the 
current study, several lines of evidence support a role for PKB as the eNOS Ser615 kinase; i) infection 
with Ad.PKB-DN reduced insulin-stimulated Ser615 phosphorylation; ii) insulin-stimulated Ser615 and 
Ser1177 phosphorylation were concomitant and VEGF, which activates PKB in HAECs stimulated 
Ser615 phosphorylation  [13]; iii) infection with Ad.PKB-CA stimulated eNOS Ser615 phosphorylation; 
iv) insulin-stimulated phosphorylation of both eNOS at Ser615 and PKB at Ser473 is attenuated in 
HAECs preincubated with TNFa. Activation of AMPK with phenformin had no effect on Ser615 
phosphorylation, indicating that unlike Ser1177, Ser615 is not a substrate for AMPK, yet we cannot rule 
out the possibility that a protein kinase downstream of PKB is responsible for insulin-stimulated Ser615 
phosphorylation   
Insulin-stimulated Ser1177 phosphorylation was unaffected by high glucose conditions, as 
described previously [6].  Furthermore, there was no significant change in either basal or insulin-
stimulated Ser615 phosphorylation in response to high glucose, suggesting that Ser615 phosphorylation is 
not impaired under high glucose culture conditions.  Indeed, as PKB is likely to be responsible for both 
Ser1177 and Ser615 phosphorylation, it is expected that phosphorylation at both sites is unaffected. 
 NO synthesis by ADP-Sepharose-purified eNOS from unstimulated HeLa cell lysates was 
unaffected when eNOS was mutated to Ala615 or Asp615.  However, in eNOS Asp1177 mutants, the 
introduction of an additional Ala615 mutation significantly reduced NO synthesis at 20-100 nM CaM, 
whereas the introduction of an additional Asp615 mutation increased maximal NO synthesis. In previous 
studies, the Asp617 mutation (bovine sequence) has been reported to increase the Ca2+-sensitivity of 
eNOS [10] or increase the Vmax of eNOS [9] in cell-free extracts. Very recently, it was reported that an 
Asp617/Asp1179 double mutant co-operatively increased Ca2+-sensitivity of eNOS compared to either 
mutation alone [18], in agreement with the current study. In intact HeLa cells transfected with eNOS 
mutants, insulin -stimulated NO synthesis by the Ala615 mutant was impaired compared to the wild type 
enzyme, whereas the Asp615 mutant alone had no significant effect on basal or insulin-stimulated NO 
synthesis.  Previous studies have reported a reduction in eNOS Vmax (as assessed by citrulline 
production), yet modestly increased NO synthesis under ATP-stimulated conditions in COS cells 
expressing an eNOS Ala617 mutant  [9].  Infection of BAECs with adenoviruses expressing Asp617 
mutant eNOS has been reported to significantly increase NO synthesis [19]. In addition, mutants in which 
Ser617, Ser635 and Ser1177 were all mutated to Ala, demonstrated reduced basal and ionomycin-
stimulated NO synthesis when compared with wild type enzyme [20]. In the current study, we have 
assayed eNOS-associated and cellular NO synthesis by a subtly different method.  It is possible that the 
different assay methods, eNOS constructs used and stimuli may underlie the lack of effect of Asp615 on 
the Ca2+-sensitivity or maximum rate of NO synthesis observed in this study.  
In agreement with our previous study, Thr495 phosphorylation was unaffec ted by high glucose or 
insulin  [6].  Similar studies in HUVECs have demonstrated a rapid dephosphorylation of Thr495 in 
response to insulin that was maximal within 2 min [21-22].  The reasons for these conflicting data are 
uncertain, although the different vessels from which the cells were isolated or time course of insulin 
stimulation may underlie this.  Phosphorylation at Ser114 (bovine sequence Ser116) has been 
demonstrated to be reduced in response to endostatin and VEGF in BAECs [17,23].  Insulin stimulated a 
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modest reduction in Ser114 phosphorylation under high glucose conditions.  Both dephosporylation 
[17,23] and phosphorylation [24] of Ser114 has been reported under conditions that activate eNOS, 
although infection with adenoviruses expressing Asp116 mutant eNOS increased the association of eNOS 
with caveolin -1 and impaired NO synthesis in BAECs and impaired relaxation in aortic rings from eNOS 
knockout mice, indicating that Ser114 phosphorylation is inhibitory [19].   
In conclusion, we propose that upon insulin-mediated PKB stimulation, phosphorylation of both 
Ser615 and Ser1177 will increase NO synthesis when compared to agents that stimulate Ser1177 alone, 
whereas phosphorylation of Ser615 alone is not sufficient to stimulate eNOS activity. Further work is 
necessary to identify the insulin signalling mechanisms impaired by high glucose culture conditions.  
Such studies should include an analysis of the regulation of subcellular localisation of eNOS and/or 
association of eNOS with caveolin-1 and/or Hsp90 [25-26]. 
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Table  1 The effect of Ser615/Ser1177 phosphorylation on NO synthesis 
 
HeLa cells were transfected with eNOS mutants and lysates prepared. Lysates were assessed for NO 
synthesis in the presence of 0-200 nM CaM.  Values stated are the mean ± SD nmol NO2-/hr/mg lysate 
and results from three independent experiments are shown. *p<0.05 relative to value in wild type (WT), 
**p<0.05 relative to value in Asp1177 mutant. 
 
 
Calmodulin (nM) 0 10 20 100  200 
Untransfected 0.20 ± 0.06 0.20 ± 0.05 0.19 ± 0.06 0.24 ± 0.04 0.22 ± 0.05 
Wild type 0.60 ± 0.14 0.74 ± 0.06 1.64 ± 0.29 2.54 ± 0.13 3.38 ± 0.40 
Ala615 0.53 ± 0.17 0.67 ± 0.18 1.45 ± 0.15 2.37 ± 0.04 2.73 ± 0.33 
Asp615 0.72 ± 0.17 0.95 ± 0.27 1.72 ± 0.56 2.76 ± 0.17 3.63 ± 0.16 
Ala1177  0.57 ± 0.24 0.76 ± 0.20 1.36 ± 0.27 2.08 ± 0.50 2.41 ± 0.34* 
Asp1177  0.84 ± 0.05 2.80 ± 0.63* 5.81 ± 0.33* 5.50 ± 0.58* 6.29 ± 1.65* 
Ala615 Ala1177 0.35 ± 0.26 0.57 ± 0.14 1.18 ± 0.23 1.53 ± 0.29 2.41  ± 0.40 
Ala615 Asp1177 0.65 ± 0.16 1.99 ± 0.60 4.02 ± 0.33** 4.63 ± 0.32** 5.21 ± 1.50 
Asp615 Ala1177 0.63 ± 0.28 1.01 ± 0.43 1.42 ± 0.24 2.24 ± 0.55 2.56 ± 0.35 
Asp615 Asp1177 0.89 ± 0.28 3.52 ± 0.91 5.79 ± 0.73 8.47 ± 1.15** 9.77 ± 0.73** 
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FIGURE LEGENDS 
 
Figure 1   The effect of insulin  on eNOS phosphorylation in HAECs  
HAECs were incubated in 5 mM glucose, 5 mM glucose + 20 mM mannitol (man) or 25 mM glucose 
(glc) for 48 h and subsequently incubated in the presence or absence of insulin (ins, 1 mM, 10 min).  
Lysates were prepared and subjected to immunoblotting with antibodies raised against phosphorylated 
eNOS at the sites indicated.  A) Representative immunoblots are shown. B) Quantification of 
immunoblots from six (Thr495, Ser633, Ser1177) or eight (Ser114, Ser615)  independent experiments 
*p<0.05 relative to value in absence of insulin. **p<0.05 relative to value in absence of high glucose. 
 
Figure 2 Insulin-stimulated eNOS Ser615 phosphorylation is PI3K/PKB -dependent 
Lysates were subjected to immunoblotting with the indicated antibodies after preparation from 
HAECs A, B) incubated in the presence or absence of insulin (1 mM, 10 min) and wortmannin (100 
nM, 45 min) or C, D) infected with the indicated adenoviruses for 48 h, prior to incubation in the 
presence or absence of insulin (1 mM, 15 min). A, C) Representative immunoblots are shown. B, D) 
Quantification of immunoblots from three independent experiments. *p<0.05 relative to vehicle, 
**p<0.05 relative to absence of wortmannin, ***p<0.05 relative to value in presence of Ad.control. 
 
Figure 3 Effect of TNFa  and phenformin on Ser615 phosphorylation  
HAEC lysates were subjected to immunoblotting with the indicated antibodies after preparation from 
HAECs preincubated in the presence or absence of A) 2 mM phenformin for 30 min or B, C) TNFa 
(10 ng/ml, 6h) and insulin (1 mM, 10 min). A , B) Representative immunoblots are shown, repeated on 
three occasions. C) Quantification of immunoblots for eNOS S615 (white bars) or PKB S473 
phosphorylation. *p<0.01 relative to vehicle, **p<0.05 relative to absence of TNFa , $p<0.01 relative 
to absence of TNFa .  
 
Figure 4 Transfection of HeLa cells with eNOS Ser615 and Ser1177 mutants 
HeLa cells were transfected with the eNOS mutants indicated, stimulated with insulin (1 mM, 10 min) 
and A) lysates prepared or B) NO synthesis assessed. A) Lysates were subjected to immunoblotting 
with the antibodies indicated.  Representative immunoblots are shown from three independent 
experiments. B) Results are shown from three independent experiments. *p<0.05 relative to absence 
of insulin, **p<0.05 relative to wild type value. 
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